Medicines of the Future, How to sustain pharmaceutical innovation and improve access and affordability ?

Please, tell us a bit more about you



EnergyIndustryEnvironmentDigitalHealth


Yes, i agree to receive email from The European FilesI also agree to receive email from The European Files's partners

We will contact you to send by postal the requested number of hard copy of this issue.

Note that due to postage fee, a minimum charge of 15€ applies

The future of healthcare in Europe depends on its sustainability and flexibility. The European Union (EU) is responsible to approach sustainability through a cost-effective framework that should minimize inequality within and across national boundaries. Flexibility is a consideration of accessibility for all patients, including those carrying rare diseases. In both these objectives, quality is key. Quality in vaccines and other medicines solutions requires months, if not years, of research and development (R&D) coupled with extended periods of rigorous testing. These could be considered barriers to innovation, though these costs ensure that only the very best products are released to patients. However as competition in the medicines R&D decreases, success rates in the deployment of medicines also declines. This means European patients are left with fewer medicines and generally higher costs. The European Commission is acutely aware of the need to redistribute these costs while continuing to motivate large amounts of investment in R&D. The solutions explored in this issue of The European Files maintain patient involvement in innovation as central to a more effective medicines development policy…

TABLE OF CONTENTS
  • Gearing up to address the challenges of future pharmaceutical innovation
    Chris Fearne, Minister for Health, Malta
  • Ensuring universal and affordable access to safe and innovative medicines
    Vytenis Andriukaitis, EU Commissioner for Health and Food Safety
  • Citizens’ access to pharmaceutical innovations
    Dolors Montserrat, Spanish Minister for Health, Social Services and Equality
  • Keeping the focus on patients’ wellbeing – how regulatory tools can help patients in need to access new medicines earlier
    Guido Rasi, Executive Director of EMA
  • Towards a new concept: Value Informed and A ordable prices for medicines
    Lieven Annemans, Professor of Health Economist, Ghent University
  • EU incentives for Innovation in pharmaceuticals – especially needed for human antibiotics
    Peter Liese, (EPP Group), Member of the ENVI Committee
  • Paediatric Regulation – A Better Application for More Efficient Incentives
    Geneviève Michaux, Member of the Brussels and Paris Bar Partner, Mayer Brown Europe-Brussels LLP
  • Paediatric Drugs: Improving Regulation for Better Application
    Glennis Willmott, MEP (S&D), Member of the ENVI Committee
  • Medicines play an important role in the lives of the citizens
    Soledad Cabezón Ruiz, MEP (S&D), Member of the ENVI Committee – Rapporteur of the European Parliament own initiative (INI) report on Access to Medicines.
  • Investment and incentives in 21st century pharmaceutical research in Europe: the cost of opportunity
    Paolo Morgese, Deerfield Management Director of Market Access
  • Vaccines and public health: how to find the right balance between access, a ordability and innovation ?
    Corinne Bardone Pharm.D, Head of Global Vaccines Public Affairs for Polio, Pertussis and Hib Vaccines – Sanofi Pasteur
    Richard Pilsudski Ph.D, Vice President, Head Global Regulatory A airs – Sanofi Pasteur
  • Reaping the benefits of healthcare biotechnology in Europe
    Nathalie Moll, Secretary General of Europabio
  • Delivering next generation of immuno-oncology therapies in managing cancer
    Hatem A. Azim, Medical Director Clinical Development, Innate Pharma
    Pierre Dodion, Executive Vice President and Chief Medical Officer, Innate Pharma
  • European Reference Networks: a way forward in the treatment of rare diseases
    Françoise Grossetete, MEP, Vice-President of the EPP Group, member of the ENVI Committee
  • Open Innovation for a Strong R&D network
    Lieve Wierinck, MEP(ALDE Group), Member of the Committee ITRE
  • A tale of two horizons – patient access in the age of innovation
    Thomas Allvin, Director Healthcare Systems European Federation of Pharmaceutical Industries and Associations
  • The Innovative Medicines Initiative – putting patients at the centre
    Pierre Meulien, IMI Executive Director
  • Ensuring equal access and catering to the needs of patients in smaller EU Member States
    Andrey Kovatchev, MEP (EPP Group), Substitute of the ENVI Committe – EP Presidency Member (Quaestor)
  • Access to Quality Care: The Patients’ View
    Nicola Bedlington, EPF Secretary General
  • The Importance of Involving Patient Organisations in Health Technology Assessment
    Lydia Makaroff, Director, European Cancer Patient Coalition
    Francesco Florindi, Head of EU Affairs, European Cancer Patient Coalition
  • Increased transparency in development and pediatric medical research processes
    Nessa Childers, MEP (S&D), Member of the ENVI Committee
  • Incentive innovation and research in the medicines to boost the competitiveness
    Patrizia Toia, MEP (S&D), Vice-Chair of Committee on Industry, Research and Energy
  • Access to Medicines at Sustainable Price: Pharma Industry and Governments Transforming Challenges into Opportunities
    Jacek Glinka, Interview of Jacek Glinka, President, Medicines for Europe
  • What about access and a offordability of medicines in the WHO European region
    Zsuzsanna Jakab, WHO Regional Director for Europe
  • Should affordability come from the European legislator?
    Karin Kadenbach, MEP (S&D), Member of the ENVI Committee
  • Ensure that new treatments will reach patients equally in every corner of the EU”
    Cristian Busoi, MEP (EPP Group), Member of the ITRE Committe
  • A positive agenda for better and affordable medicines in Europe
    Yannis Natsis, Policy Manager for Universal Access and A ordable Medicines, European Public Health Alliance (EPHA)